| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex® DM Maximum...
-
Mar 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the 2018 Barclays Global Healthcare Conference at 1:35 PM EST on...
-
Mar 1, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission and...
-
Mar 1, 2018
Fourth Quarter Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion, reported net income of $73 million and reported diluted earnings per share ("EPS") of $0.52 compared to a...
-
Feb 27, 2018Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018
Select Preliminary Unaudited Calendar Year 2017 Results Delivered strong calendar year 2017 GAAP ("reported") and adjusted net sales at the high end of previous guidance range and operating cash...